Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Testing transparency Testing references may be present, but batch-level visibility and clear, easy-to-verify third-party documentation are limited
May reduce efficacy of thyroid hormone replacement when co-administered
Some women experience high blood sugar during pregnancy
Guillevin et al., 2011
Why Sermorelin Has a Favorable Long-Term Profile Several pharmacological characteristics contribute to sermorelins safety over time: Self-regulating mechanism: The hypothalamic-pituitary feedback loop prevents excessive GH accumulation Pulsatile release pattern: Mimics natural physiology rather than creating sustained supraphysiological levels No exogenous hormone: The body produces its own GH, maintaining receptor sensitivity No suppression of endogenous production: Unlike exogenous HGH, sermorelin does not suppress the pituitarys own GHRH responsiveness Long-Term Monitoring Recommendations For patients on extended sermorelin protocols, recommended monitoring includes: IGF-1 levels: Checked every 3-6 months to ensure levels remain within normal ranges (typically targeting the upper third of the age-adjusted reference range) Fasting glucose and HbA1c: GH can influence insulin sensitivity
